Multiple pre-exposure (PrEP) and postexposure (PEP) treatments are now available to prevent HIV infection. An updated Canadian guideline published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.250511 contains 31 recommendations and 10 good practice… read more.
Shionogi & Co., Ltd. announced the launch of a new formulation of the anti-influenza virus drug Xofluza (baloxavir marboxil) – Xofluza Granules 2%. Until now, Xofluza has only… read more.
Novo Nordisk announced that the FDA approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients… read more.
Preexposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV acquisition.1 Multiple PrEP medications have recently become available in the US, including 3 oral options with comparable safety… read more.
Octapharma USA announced the expansion of the FDA approval for wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label… read more.
Results of a qualitative research study into the uptake of PrEP – a drug which stops HIV infecting the body – suggests that more needs to be done… read more.
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
Professor Colleen Aldous is a research professor at in the School of Clinical Medicine at the University of Kwazulu-Natal in South Africa. She recently described the SAIVE trial… read more.
Colleen Aldous, Professor for Medical Research, University of KwaZulu-Natal explains how the evidence supporting the use of ivermectin for covid-19 came together to tell a compelling story. In… read more.
When assessing repurposed drugs in a pandemic situation, the totality of evidence should be considered rather than RCTs alone; had this been done the pandemic could have been… read more.
The TOGETHER trial was widely reported as showing that ivermectin was not effective in covid-19, but a straightforward analysis of the results reveals a 59 per cent reduction… read more.
The best time to administer ivermectin is at the beginning of a covid-19 infection so that virus is killed and disease progression averted, according to Colleen Aldous, Professor… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
